La Jolla Pharmaceutical (LJPC) 10-Q 29 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 23, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	LA JOLLA PHARMACEUTICAL CO
Entity Central Index Key	920465
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		15,250,840

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$42,712	$48,555
Restricted cash	37	37
Prepaid clinical expenses	1,449	1,528
Prepaid expenses and other current assets	622	137
Total current assets	44,820	50,257
Equipment and furnishings, net	659	279
Other assets	57	0
Total assets	45,536	50,536
Current liabilities:
Accounts payable	2,459	730
Accrued expenses	117	926
Accrued payroll and related expenses	0	424
Total current liabilities	2,576	2,080
Shareholders’ equity:
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 15,250,840 and 15,225,980 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	2	2
Additional paid-in capital	531,873	528,353
Accumulated deficit	-495,569	-486,614
Total shareholders’ equity	42,960	48,456
Total liabilities and shareholders' equity	45,536	50,536
Series C-1 Convertible Preferred Stock [Member]
Shareholders’ equity:
Convertible preferred stock, value	3,917	3,917
Series F Convertible Preferred Stock [Member]
Shareholders’ equity:
Convertible preferred stock, value	$2,737	$2,798

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	15,250,840	15,225,980
Common stock, shares outstanding	15,250,840	15,225,980
Preferred stock, par value	$0.00
Preferred stock, shares authorized	8,000,000
Series C-1 Convertible Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	11,000	11,000
Preferred stock, shares issued	3,917	3,917
Preferred stock, shares outstanding	3,917	3,917
Series F Convertible Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	2,737	2,798
Preferred stock, shares outstanding	2,737	2,798

Unaudited_Condensed_Statements

Unaudited Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Expenses:
Research and development	$5,170	$1,996
General and administrative	3,796	3,134
Total expenses	8,966	5,130
Loss from operations	-8,966	-5,130
Other income, net	11	2
Net loss and comprehensive loss	($8,955)	($5,128)
Basic and diluted net loss per share (usd per share)	($0.59)	($0.93)
Shares used in computing basic and diluted net loss per share	15,242	5,535

Unaudited_Condensed_Statements1

Unaudited Condensed Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating activities
Net loss	($8,955)	($5,128)
Adjustments to reconcile net loss to net cash used for operating activities:
Share-based compensation expense	2,906	2,673
Third party share-based compensation expense	496	0
Issuance of common stock for services	0	25
Depreciation expense	11	2
Changes in operating assets and liabilities:
Prepaid clinical expenses	79	0
Prepaid expenses and other current assets	-485	-113
Other assets	-57	0
Accounts payable	1,729	-272
Accrued expenses	-809	75
Accrued payroll and related expenses	-424	9
Net cash used for operating activities	-5,509	-2,729
Investing activities
Purchase of property and equipment	-391	-15
Net cash used for investing activities	-391	-15
Financing activities
Net proceeds from the exercise of stock options for common stock	57	0
Net cash provided by financing activities	57	0
Net decrease in cash and cash equivalents	-5,843	-2,744
Cash and cash equivalents at beginning of period	48,555	8,629
Cash, cash equivalents at end of period	42,712	5,885
Conversion of Series C-1 and D-1 Preferred Stock into Common Stock [Member]
Non-cash investing and financing activity
Conversion of stock	0	1,623
Conversion of Series F Preferred Stock into Common Stock [Member]
Non-cash investing and financing activity
Conversion of stock	$61	$184

Business

Business	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	Business
	La Jolla Pharmaceutical Company (the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company was incorporated in 1989 as a Delaware corporation. On June 7, 2012, the Company reincorporated in the State of California.
	The Company has a history of incurring significant operating losses and negative cash flows from operations. Since January 2012, when the Company was effectively restarted with new assets and a new management team, through March 31, 2015, the Company's cash used in operating activities was $25.2 million. In July 2014, the Company completed a common stock offering and received approximately $53.1 million, net of issuance costs (see Note 3). As of March 31, 2015, the Company had available cash and cash equivalents of $42.7 million. Management believes that the available cash and cash equivalents will be sufficient to fund operations through 2016; provided, however, that if the Company pursues additional clinical trials other than those planned for the Company's current product candidates, or if the Company adds additional product candidates prior to the end of 2016, the Company will need to raise additional capital.
	Effective January 14, 2014, the Company effected a 1-for-50 reverse split (the "2014 Reverse Stock Split") of its outstanding common stock (See Note 3). All common stock share and per share information in the accompanying unaudited condensed financial statements have been restated to reflect retrospective application of the 2014 Reverse Stock Split for all periods presented, except for par value per share and the number of authorized share amounts, which were not affected. All stock options and the shares of common stock underlying outstanding convertible preferred stock were appropriately adjusted to give effect to the 2014 Reverse Stock Split.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Basis of Presentation and Use of Estimates
	The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission ("SEC") Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the SEC on March 16, 2015. The unaudited financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed balance sheet of the Company at March 31, 2015, the condensed statements of operations and comprehensive loss for the three months ended March 31, 2015, and the condensed statement of cash flows for the three months ended March 31, 2015. Estimates were made relating to useful lives of fixed assets, valuation allowances, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods.
	Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders' equity or cash flows.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. The carrying value of the Company's money market funds is included in cash equivalents and approximates the fair value.
	Restricted Cash
	Under the terms of the leases of the Company's facilities, there is a requirement to maintain a certificate of deposit as security during the terms of such leases. As of March 31, 2015 and December 31, 2014, restricted cash of $37,000 was pledged as collateral for the certificate of deposit.
	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to seven years. As of March 31, 2015 and December 31, 2014, the carrying value of property and equipment, net was $659,000 and $279,000, respectively, which was comprised of lab equipment, furniture, computer equipment and software. Depreciation expense was $11,000 and $2,000 for the three months ended March 31, 2015 and 2014, respectively.
	Clinical Trial Expenses
	Payments in connection with the Company's clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. Payments under these contracts depend on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. As of March 31, 2015 and December 31, 2014, the prepaid clinical expenses of $1,449,000 and $1,528,000 on the balance sheets represent the initial upfront payments to a clinical research organization for two clinical trials that commenced in 2015. The Company amortizes prepayments to expense based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials.
	Expenses related to clinical trials are accrued based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts are modified, the accruals are modified accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision occur.
	Research and Development Expenses
	Research and development expenses include salaries and benefits, facilities and other overhead expenses, research-related manufacturing expenses, contract services and clinical and preclinical-related services performed by clinical research organizations, research institutions and other outside service providers. Research and development expenses are charged to operations as incurred when these expenditures relate to the Company's research and development efforts and have no alternative future uses.
	In accordance with certain research and development agreements, the Company is obligated to make certain upfront payments upon execution of the agreement. Advance payments, including nonrefundable amounts, for materials or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed.
	Acquisition or milestone payments that the Company makes in connection with in-licensed technology are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology. The Company considers the future economic benefits from the licensed technology to be uncertain until such licensed technology is incorporated into products that are approved for marketing by the Food and Drug Administration (the "FDA") or when other significant risk factors are abated. For accounting purposes, management has viewed future economic benefits for all of the Company's licensed technology to be uncertain.
	Share-Based Compensation
	The Company accounts for share-based payment arrangements in accordance with Accounting Standards codification ("ASC") 718, Compensation - Stock Compensation and ASC 505-50, Equity - Equity Based Payments to Non-Employees, which requires the recognition of compensation expense, using a fair-value based method, for all costs related to share-based payments, including stock options and restricted stock awards. These standards require companies to estimate the fair value of share-based payment awards on the date of the grant using an option-pricing model. See Note 3 for further discussion of the Company's share-based compensation plans.
	Net Loss Per Share
	Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding and common stock equivalents. Outstanding convertible preferred stock, stock options and unvested restricted stock awards are considered common stock equivalents and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Common stock equivalents are not included in the computation of diluted net loss per share if the inclusion of these securities is anti-dilutive. As of March 31, 2015 and March 31, 2014, there were common stock equivalents of 8.8 million shares and 10.2 million shares, respectively, which were excluded from the calculation of diluted net loss per share because they were anti-dilutive.
	Comprehensive Loss
	Comprehensive loss for the periods reported was comprised solely of the Company's net loss. The comprehensive loss for the three months ended March 31, 2015 and 2014 was $9.0 million and $5.1 million, respectively. There were no other changes in equity that were excluded from net loss for all periods.
	Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and to provide related footnote disclosures. The ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The ASU is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016, which for the Company is January 1, 2017. Early adoption is permitted. The Company does not intend to early adopt this standard. The adoption of this standard will not have a material impact on the Company's financial position or results of operations.
	In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 781): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. This update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. This update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015, which for the Company is January 1, 2016. Early adoption is permitted. Entities may apply the amendments in this update either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of this standard will not have a material impact on the Company's financial position or results of operations.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This update outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. This guidance was originally effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, which for the Company is January 1, 2017; early adoption was not permitted. In April 2015, the FASB voted to propose a deferral of the effective date of the new standard by one year, but to permit companies to adopt one year earlier if they choose. The standard may be adopted using a full retrospective or a modified retrospective (cumulative effect) method. The Company does not anticipate that the adoption of this update will have a material impact on its financial position or results of operations.

Shareholders_Equity

Shareholders’ Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Shareholders’ Equity	Shareholders’ Equity
	Common Stock
	2014 Reverse Stock Split
	On January 14, 2014, the Company enacted the 2014 Reverse Stock Split. The 2014 Reverse Stock Split was approved by the Company's shareholders on June 5, 2013, and resulted in every 50 shares of the Company’s issued and outstanding common stock to be automatically combined into one share of the Company’s common stock. No fractional shares were issued in connection with the 2014 Reverse Stock Split. Shareholders who were entitled to fractional shares instead became entitled to receive a cash payment in lieu of receiving fractional shares equal to the fractional share interest. The 2014 Reverse Stock Split affected all of the holders of the Company’s common stock uniformly. Shares of the Company’s common stock underlying outstanding stock options were proportionately reduced, and the exercise prices of outstanding stock options were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of the Company’s common stock underlying outstanding convertible preferred stock were proportionately reduced, and the conversion rates were proportionately decreased in accordance with the terms of the agreements governing such securities.
	Amendments to Articles of Incorporation
	On August 27, 2014, at the Company's annual meeting of shareholders, the Company's shareholders approved an amendment to the Company's articles of incorporation to reduce the number of authorized common shares available for issuance to 100,000,000 shares from 12,000,000,000 shares.
	2014 Common Stock Offering
	In July 2014, the Company entered into an underwriting agreement, in which the Company agreed to issue and sell an aggregate of 4,800,000 shares of its common stock. Under the terms of the underwriting agreement, the Company granted the underwriters an option for 30 days to purchase up to an additional 720,000 shares of the Company's common stock. On July 23, 2014, the underwriters partially exercised their option to purchase an additional 595,000 shares of the Company's common stock. The shares were sold at a public offering price of $10.50 per share, with gross proceeds of approximately $56.6 million. This transaction closed on July 28, 2014, and the Company received total net proceeds of approximately $53.1 million, net of approximately $3.5 million in underwriting commissions, discounts and other issuance costs.
	Preferred Stock
	As of March 31, 2015, the Company is authorized to issue 8,000,000 shares of preferred stock, with a par value of $0.0001 per share, in one or more series, of which 11,000 are designated Series C-12 Convertible Preferred Stock (the "Series C-12 Preferred") and 10,000 are designated Series F Convertible Preferred Stock (the "Series F Preferred"). During the three months ended March 31, 2015, the Company issued 17,360 shares of common stock upon the conversion of Series F Preferred. During the year ended December 31, 2014, the Company issued 5,341,670 shares of common stock upon the conversion of Series C-12 Preferred and 129,105 shares of common stock upon the conversion of Series F Preferred. The Series C-12 Preferred is convertible into common stock at a rate of 1,724 shares of common stock for each share of Series C-12 Preferred, and the Series F Preferred is convertible into common stock at a rate of 286 shares of common stock for each share of Series F Preferred. As of March 31, 2015, there were 3,917 shares of Series C-12 Preferred and 2,737 shares of Series F Preferred issued and outstanding. As such, as of March 31, 2015, the issued and outstanding Series C-12 Preferred and Series F Preferred were convertible into 6,752,908 and 782,032 shares of common stock, respectively.
	The holders of preferred stock do not have voting rights, other than for general protective rights required by the California General Corporation Law. The Series C-12 Preferred and the Series F Preferred do not have dividends.
	The Series C-12 Preferred and the Series F Preferred have a liquidation preference in an amount equal to $1,000 per share. As of March 31, 2015, the aggregate liquidation preference was $3,917,000 and $2,737,000 on the Series C-12 Preferred and Series F Preferred, respectively.
	Share-Based Compensation
	Stock Options
	2013 Equity Incentive Plan
	In September 2013, the Company adopted an equity compensation plan entitled the 2013 Equity Incentive Plan (the “2013 Equity Plan”). The 2013 Equity Plan is an omnibus equity compensation plan that permits the issuance of various types of equity-based compensation awards, including stock options, restricted stock awards, stock appreciation rights and restricted stock units, as well as cash awards, to employees, directors and eligible consultants of the Company. The 2013 Equity Plan has a ten-year term and permits the issuance of incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended. The administrator under the plan has broad discretion to establish the terms of awards, including the size, term, exercise price and vesting conditions. Generally, grants to employees vest over four years, with 25% vesting on the one-year anniversary, and the remainder vesting either quarterly or monthly thereafter; grants to non-employee directors vest over three years, with 33% vesting on the one-year anniversary, and the remainder vesting either quarterly or monthly thereafter.
	The 2013 Equity Plan previously allowed for automatic annual increases to the number of shares of common stock authorized for issuance under the plan on the first day of each year, with such increases based on 10% of the outstanding shares of the Company’s common stock as of the last day of the previous year end. On January 1, 2014, the total shares available for grant under the 2013 Equity Plan increased to 440,441. At the 2014 annual meeting of shareholders, the Company's shareholders approved and adopted an amendment to the 2013 Equity Plan to increase the number of shares of common stock authorized for issuance up to a total of 1,100,000 shares and eliminated the automatic annual increase on the first day of each year.
	As of March 31, 2015, there were 208,204 shares available for future grants under the 2013 Equity Plan.
	Total share-based compensation expense related to all share-based awards for the three months ended March 31, 2015 and 2014 was comprised of the following (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Research and development:
	Stock options	$	558		$	8
	Restricted stock	478			359
	Warrants	11			—
	Research and development share-based compensation expense	1,047			367
	General and administrative:
	Stock options	589			23
	Restricted stock	1,579			2,308
	Warrants	187			—
	General and administrative share-based compensation expense	2,355			2,331
	Total share-based compensation expense included in expenses	$	3,402		$	2,698
	The Company’s 2013 Equity Plan stock option and restricted stock award activity for the three months ended March 31, 2015 and the year ended December 31, 2014 was comprised of the following:
		Outstanding Stock Options and Restricted Stock Awards
		Shares			Weighted-Average Exercise Price per Share		Weighted-	Aggregate
		Underlying					Average	Intrinsic
		Stock Options and Restricted Stock Awards					Remaining	Value
							Contractual
							Term
	Outstanding at December 31, 2013	54,000			$6.00
	Granted	567,876			$9.88
	Restricted stock awards	(2,976	)		$0.00
	Outstanding at December 31, 2014	618,900			$9.54
	Granted	577,600			$19.50
	Exercised	(7,500	)		$7.63
	Forfeited	(7,500	)		$7.63
	Outstanding at March 31, 2015	1,181,500			$14.43		9.50 years	$	5,318,774
	Vested and expected to vest at March 31, 2015	1,181,500			$14.43		9.50 years	$	5,318,774
	Exercisable at March 31, 2015	44,127			$10.19		9.11 years	$	358,024
	During February 2015, the Company made a stock option grant to the Company's Chief Executive Officer to purchase 300,000 shares of common stock at an exercise price equal to the fair market value of the Company's stock on the date of grant. The grant was made under the 2013 Equity Plan. However, due to the fact that the share reserve in the plan had been exhausted at that time, the grant was made subject to shareholder approval, which must be obtained within one year from the date of grant. The stock option will vest and become exercisable with respect to 25% of the underlying shares on the first anniversary of the date of grant, and then with respect to the remaining shares, on a quarterly basis over the next three years, subject to continued service during that time. The Company intends to seek shareholder approval of an increase in the share reserve under the 2013 Equity Plan at the Company's 2015 annual meeting of shareholders.
	Share-based compensation expense recognized in the statements of operations and comprehensive loss for the three months ended March 31, 2015 and the year ended December 31, 2014 is based on awards ultimately expected to vest. There were no forfeitures during 2014.
	As of March 31, 2015, the Company has reserved 1,089,524 shares of common stock for future issuance upon exercise of all outstanding stock options granted or to be granted under the 2013 Equity Plan, which excludes the 300,000 shares underlying the stock option issued in February 2015.
	The weighted-average grant date fair values of stock options granted during the three months ended March 31, 2015 and 2014 was $18.89 and $7.51 per share, respectively. As of March 31, 2015, approximately $14,396,000 of total unrecognized compensation costs related to non-vested stock options is expected to be recognized over a weighted-average period of approximately 3.4 years. During the three months ended March 31, 2015, stock options to purchase 7,500 shares of common stock were exercised with an intrinsic value of $111,000. No stock option exercises occurred during the year ended December 31, 2014.
	The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option pricing model (the “Black-Scholes model”), which uses the assumptions noted in the following table. Expected volatility is based on historical volatility of the Company’s Common Stock. In determining the expected life of employee stock options, the Company uses the “simplified” method. The expected life assumptions for non-employees were based upon the contractual term of the stock options. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the stock options in effect at the time of the grants. The dividend yield assumption is based on the expectation of no future dividend payments by the Company.
	The Company estimated the fair value of each stock option grant on the date of grant using the Black-Scholes model with the following weighted-average assumptions:
		March 31,
		2015		2014
	Volatility	174	%	132	%
	Expected life (years)	6.82 years		6.11 years
	Risk-free interest rate	1.8	%	1.9	%
	Dividend yield	—	%	—	%
	Third Party Share-based Compensation Expense
	The Company initially estimates the fair value of stock options, warrants or stock awards issued to non-employees, other than non-employee directors, on the date of grant using the Black-Scholes model; and thereafter, the Company re-measures the fair value as of each balance sheet date as the stock options and warrants vest.
In December 2014, the Company granted warrants to purchase 51,000 shares of common stock to two outside third parties at an exercise price equal to the fair market value of the stock at the date of each grant. One grant will vest 25% on each anniversary date over four years. The second grant vests 100% on the one-year anniversary of the grant. The Company recognized compensation expense for these warrant grants of approximately $198,000 for the three months ended March 31, 2015.
During the three months ended March 31, 2015, the Company granted a stock option to purchase 60,000 shares of common stock to a consultant at an exercise price equal to the fair market value of the Company's common stock at the date of grant. This grant was made from the 2013 Equity Plan. The stock option vested 25% upon grant, and the remainder will vest quarterly over three years. The Company recognized compensation expense for this stock option grant of approximately $298,000 for the three months ended March 31, 2015.
Restricted Stock Awards
Restricted stock awards are grants that entitle the holder to acquire shares of common stock for no cash consideration or at a fixed price, which is typically nominal. The Company accounts for the restricted stock awards as issued and outstanding common stock, even though the shares covered by a restricted stock award cannot be sold, pledged, or otherwise disposed of until the award vests, and any unvested shares may be reacquired by the Company for the original purchase price following the awardee's termination of service.
On September 24, 2013, the Company issued restricted stock awards ("RSAs") of approximately 1,327,048 shares to an officer, 79,622 shares to a director and an aggregate of 336,185 shares to three employees. The grants to the officer, director and one of the employees were for the replacement of canceled stock options and restricted stock units granted on April 10, 2012, which was done in order to complete the capital restructuring that took place in September 2013. The RSAs were granted outside of the 2013 Equity Plan, but are governed in all respects by the 2013 Equity Plan. The RSAs were granted with a combination of performance-based and time-based vesting components. During the year ended December 31, 2014, all of the performance-based vesting components were either achieved or modified to time-based vesting, and the RSAs will be fully vested within approximately 13 months.
On January 25, 2014, the Company granted RSAs representing 2,976 shares of common stock with a grant date fair market value of $25,000 to a consultant for services. The RSAs vested immediately and were issued under the 2013 Equity Plan.
The Company’s restricted stock award activity for the three months ended March 31, 2015 and the year ended December 31, 2014 was comprised of the following:
	Number of Shares		Weighted-Average Grant Date Fair Value
Unvested at December 31, 2013	1,746,853		$	11.8
Granted	2,976		$	8.4
Vested	(423,693	)	$	9.18
Forfeited	(47,129	)	$	4.41
Unvested at December 31, 2014	1,279,007		$	12.86
Vested	(153,026	)	$	12.87
Unvested at March 31, 2015	1,125,981		$	12.86
The remaining unrecognized share-based compensation expense for research and development activities attributable to RSAs to be recognized over the next 10 months is approximately $1,060,000. The remaining unrecognized share-based compensation expense for general and administrative activities attributable to RSAs to be recognized over the next 10 months is approximately $5,257,000.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	Deferred income tax assets and liabilities are recognized for temporary differences between financial statement and income tax carrying values, using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding the Company's ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of March 31, 2015.
	The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There have been no material changes in the Company's unrecognized tax benefits since December 31, 2014; and, as such, disclosures included in the Company's 2014 Annual Report on Form 10-K continue to be relevant for the period ended March 31, 2015.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	On January 30, 2015, the Company entered into a 25-month lease agreement for 4,047 square feet of lab space. The lease term is from March 2015 through March 2017, and the Company's total lease payments through the end of the lease will be approximately $93,000. The lease contains options to extend the lease for two additional six-month periods.
	On February 24, 2015, the Company entered into a 32-month sublease agreement as a sublessee for 18,599 square feet of office space to be used as the Company's corporate headquarters. The lease term is through October 2017, and the Company's total lease payments through the end of the lease will be approximately $1,466,000. The Company also leases a total of 3,713 square feet of office space with a lease term through March 2018, and total lease payments through the end of the lease are approximately $300,000.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation and Use of Estimates
	The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission ("SEC") Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the SEC on March 16, 2015. The unaudited financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed balance sheet of the Company at March 31, 2015, the condensed statements of operations and comprehensive loss for the three months ended March 31, 2015, and the condensed statement of cash flows for the three months ended March 31, 2015. Estimates were made relating to useful lives of fixed assets, valuation allowances, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods.
	Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders' equity or cash flows.
Use of Estimates	Basis of Presentation and Use of Estimates
	The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission ("SEC") Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the SEC on March 16, 2015. The unaudited financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed balance sheet of the Company at March 31, 2015, the condensed statements of operations and comprehensive loss for the three months ended March 31, 2015, and the condensed statement of cash flows for the three months ended March 31, 2015. Estimates were made relating to useful lives of fixed assets, valuation allowances, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods.
	Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders' equity or cash flows.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. The carrying value of the Company's money market funds is included in cash equivalents and approximates the fair value.
Restricted Cash	Restricted Cash
	Under the terms of the leases of the Company's facilities, there is a requirement to maintain a certificate of deposit as security during the terms of such leases.
Property and Equipment	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to seven years.
Clinical Trial Expenses	Clinical Trial Expenses
	Payments in connection with the Company's clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. Payments under these contracts depend on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. As of March 31, 2015 and December 31, 2014, the prepaid clinical expenses of $1,449,000 and $1,528,000 on the balance sheets represent the initial upfront payments to a clinical research organization for two clinical trials that commenced in 2015. The Company amortizes prepayments to expense based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials.
	Expenses related to clinical trials are accrued based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts are modified, the accruals are modified accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision occur.
Research and Development Expenses	Research and Development Expenses
	Research and development expenses include salaries and benefits, facilities and other overhead expenses, research-related manufacturing expenses, contract services and clinical and preclinical-related services performed by clinical research organizations, research institutions and other outside service providers. Research and development expenses are charged to operations as incurred when these expenditures relate to the Company's research and development efforts and have no alternative future uses.
	In accordance with certain research and development agreements, the Company is obligated to make certain upfront payments upon execution of the agreement. Advance payments, including nonrefundable amounts, for materials or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed.
	Acquisition or milestone payments that the Company makes in connection with in-licensed technology are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology. The Company considers the future economic benefits from the licensed technology to be uncertain until such licensed technology is incorporated into products that are approved for marketing by the Food and Drug Administration (the "FDA") or when other significant risk factors are abated. For accounting purposes, management has viewed future economic benefits for all of the Company's licensed technology to be uncertain.
Share-Based Compensation	Share-Based Compensation
	The Company accounts for share-based payment arrangements in accordance with Accounting Standards codification ("ASC") 718, Compensation - Stock Compensation and ASC 505-50, Equity - Equity Based Payments to Non-Employees, which requires the recognition of compensation expense, using a fair-value based method, for all costs related to share-based payments, including stock options and restricted stock awards. These standards require companies to estimate the fair value of share-based payment awards on the date of the grant using an option-pricing model. See Note 3 for further discussion of the Company's share-based compensation plans.
Net Loss Per Share	Net Loss Per Share
	Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding and common stock equivalents. Outstanding convertible preferred stock, stock options and unvested restricted stock awards are considered common stock equivalents and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Common stock equivalents are not included in the computation of diluted net loss per share if the inclusion of these securities is anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and to provide related footnote disclosures. The ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The ASU is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016, which for the Company is January 1, 2017. Early adoption is permitted. The Company does not intend to early adopt this standard. The adoption of this standard will not have a material impact on the Company's financial position or results of operations.
	In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 781): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. This update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. This update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015, which for the Company is January 1, 2016. Early adoption is permitted. Entities may apply the amendments in this update either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of this standard will not have a material impact on the Company's financial position or results of operations.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This update outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. This guidance was originally effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, which for the Company is January 1, 2017; early adoption was not permitted. In April 2015, the FASB voted to propose a deferral of the effective date of the new standard by one year, but to permit companies to adopt one year earlier if they choose. The standard may be adopted using a full retrospective or a modified retrospective (cumulative effect) method. The Company does not anticipate that the adoption of this update will have a material impact on its financial position or results of operations.

Shareholders_Equity_Tables

Shareholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Share-based Compensation Expense	Total share-based compensation expense related to all share-based awards for the three months ended March 31, 2015 and 2014 was comprised of the following (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Research and development:
	Stock options	$	558		$	8
	Restricted stock	478			359
	Warrants	11			—
	Research and development share-based compensation expense	1,047			367
	General and administrative:
	Stock options	589			23
	Restricted stock	1,579			2,308
	Warrants	187			—
	General and administrative share-based compensation expense	2,355			2,331
	Total share-based compensation expense included in expenses	$	3,402		$	2,698
Summary of Stock Option Activity and Related Data	The Company’s 2013 Equity Plan stock option and restricted stock award activity for the three months ended March 31, 2015 and the year ended December 31, 2014 was comprised of the following:
		Outstanding Stock Options and Restricted Stock Awards
		Shares			Weighted-Average Exercise Price per Share		Weighted-	Aggregate
		Underlying					Average	Intrinsic
		Stock Options and Restricted Stock Awards					Remaining	Value
							Contractual
							Term
	Outstanding at December 31, 2013	54,000			$6.00
	Granted	567,876			$9.88
	Restricted stock awards	(2,976	)		$0.00
	Outstanding at December 31, 2014	618,900			$9.54
	Granted	577,600			$19.50
	Exercised	(7,500	)		$7.63
	Forfeited	(7,500	)		$7.63
	Outstanding at March 31, 2015	1,181,500			$14.43		9.50 years	$	5,318,774
	Vested and expected to vest at March 31, 2015	1,181,500			$14.43		9.50 years	$	5,318,774
	Exercisable at March 31, 2015	44,127			$10.19		9.11 years	$	358,024
Stock Options, Valuation Assumptions	The Company estimated the fair value of each stock option grant on the date of grant using the Black-Scholes model with the following weighted-average assumptions:
		March 31,
		2015		2014
	Volatility	174	%	132	%
	Expected life (years)	6.82 years		6.11 years
	Risk-free interest rate	1.8	%	1.9	%
	Dividend yield	—	%	—	%
Summary of restricted stock activity	The Company’s restricted stock award activity for the three months ended March 31, 2015 and the year ended December 31, 2014 was comprised of the following:
		Number of Shares		Weighted-Average Grant Date Fair Value
	Unvested at December 31, 2013	1,746,853		$	11.8
	Granted	2,976		$	8.4
	Vested	(423,693	)	$	9.18
	Forfeited	(47,129	)	$	4.41
	Unvested at December 31, 2014	1,279,007		$	12.86
	Vested	(153,026	)	$	12.87
	Unvested at March 31, 2015	1,125,981		$	12.86

Business_Details

Business (Details) (USD $)	0 Months Ended	3 Months Ended		39 Months Ended	0 Months Ended	1 Months Ended
	Jan. 14, 2014	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Jul. 23, 2014	Jul. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net cash used for operating activities		$5,509,000	$2,729,000	$25,209,000
Schedule of Capitalization, Equity [Line Items]
Cash and cash equivalents		42,712,000	5,885,000	42,712,000			48,555,000	8,629,000
Reverse stock split ratio	0.02
Underwriting Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Proceeds from the underwriting agreement, including additional shares sold, net of cost					$53,100,000	$53,100,000

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended
In Thousands, except Share data in Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Restricted cash	$37		$37
Property, Plant and Equipment [Line Items]
Property and equipment, net	659		279
Depreciation expense	11	2
Prepaid clinical expenses	1,449		1,528
Potentially dilutive common shares related to the outstanding preferred stock, stock options, restricted stock units and warrants	8.8	10.2
Comprehensive loss	($8,955)	($5,128)
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	2 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	7 years

Shareholders_Equity_Narrative_

Shareholders’ Equity (Narrative) (Details) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2014

Jan. 25, 2014

Feb. 28, 2015

Sep. 30, 2013

Sep. 24, 2013

Sep. 30, 2013

Jul. 23, 2014

Jul. 31, 2014

Aug. 27, 2014

Aug. 26, 2014

Jan. 02, 2014

party

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock, shares authorized

100,000,000

100,000,000

100,000,000

100,000,000

12,000,000,000

Preferred stock, shares authorized

8,000,000

Preferred stock, par value

$0.00

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$18.89

$7.51

Unamortized share-based compensation expense

$14,400,000

Recognized weighted average period

3 years 4 months 24 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

7,500

0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

111,000

Warrants Granted To Purchase Common Stock

51,000

Warrants Issued, Number of Third Party Recipients

2

Third party share-based compensation expense

198,000

496,000

0

Share-based compensation expense

3,402,000

2,698,000

Research and development [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense

1,047,000

367,000

General and administrative [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense

2,355,000

2,331,000

Stock Option [Member] | Research and development [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense

558,000

8,000

Stock Option [Member] | General and administrative [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense

589,000

23,000

Restricted Stock [Member] | Research and development [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Recognized weighted average period

10 months

Share-based compensation expense

478,000

359,000

Unamortized share-based compensation expense

1,060,000

Restricted Stock [Member] | General and administrative [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Recognized weighted average period

10 months

Share-based compensation expense

1,579,000

2,308,000

Unamortized share-based compensation expense

5,257,000

Common Stock [Member] | Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Period of share-based payment awards

13 months

Series C-1 Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Preferred stock, shares authorized

11,000

11,000

11,000

Preferred stock, par value

$0.00

$0.00

0.0001

Shares issued upon conversion, per share

1,724

Preferred stock, shares issued

3,917

3,917

3,917

Shares reserved for future issuance

6,752,908

Liquidation preference per share

$1,000

1,000

Liquidation preference

3,917,000

3,917,000

Series C-1 Preferred Stock [Member] | Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock issued

5,341,670

Series F Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Preferred stock, shares authorized

10,000

10,000

10,000

Preferred stock, par value

$0.00

$0.00

0.0001

Shares issued upon conversion, per share

286

Preferred stock, shares issued

2,798

2,737

2,798

Shares reserved for future issuance

782,032

Liquidation preference

2,737,000

2,737,000

Series F Preferred Stock [Member] | Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock issued

17,360

129,105

Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Period of share-based payment awards

3 years

Stock options granted

60,000

Share-based compensation expense

298,000

Consultant [Member] | Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock issued

2,976

Stock Issued During Period, Value, New Issues

25,000

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options granted

300,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Approval Period

1 year

Director [Member] | Common Stock [Member] | Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock issued

79,622

Employees [Member] | Common Stock [Member] | Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock issued

336,185

Officer [Member] | Common Stock [Member] | Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock issued

1,327,048

2013 Equity Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Equity plan, term

10 years

Period of share-based payment awards

4 years

Automatic annual increase based on outstanding shares of Common Stock as of the last day of the previous year end, percent

10.00%

Shares available for grant

208,204

1,100,000

440,441

Common Stock, Capital Shares Reserved for Future Issuance

1,089,524

2013 Equity Plan [Member] | Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Period of share-based payment awards

3 years

One-year Anniversary Date of Grant [Member] | Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting rights, percentage

25.00%

One-year Anniversary Date of Grant [Member] | 2013 Equity Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting rights, percentage

25.00%

One-year Anniversary Date of Grant [Member] | 2013 Equity Plan [Member] | Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting rights, percentage

33.00%

Upon Grant [Member] | Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting rights, percentage

25.00%

Underwriting Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock to be issued and sold in underwriting agreement

4,800,000

Term of option to purchase additional shares

30 days

Proceeds from the underwriting agreement, including additional shares sold, gross

56,600,000

Proceeds from the underwriting agreement, including additional shares sold, net of cost

53,100,000

53,100,000

Issuance costs

$3,500,000

IPO [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Price per share of shares sold (usd per share)

$10.50

Over-Allotment Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock to be issued and sold in underwriting agreement

595,000

Number of additional shares available

720,000

Grant One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Class of Warrant or Right, Award Vesting Period

4 years

Grant One [Member] | One-year Anniversary Date of Grant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Class of Warrant or Right, Award Vesting Rights, Percentage

25.00%

Grant Two [Member] | One-year Anniversary Date of Grant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Class of Warrant or Right, Award Vesting Rights, Percentage

100.00%

Shareholders_Equity_Sharebased

Shareholders’ Equity (Share-based Compensation Expense) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$3,402	$2,698
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	1,047	367
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	2,355	2,331
Stock Option [Member] | Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	558	8
Stock Option [Member] | General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	589	23
Restricted Stock [Member] | Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	478	359
Restricted Stock [Member] | General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	1,579	2,308
Restricted Stock Units (RSUs) [Member] | Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	11	0
Restricted Stock Units (RSUs) [Member] | General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$187	$0

Stock_Option_Award_Activity_De

(Stock Option Award Activity) (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding beginning balance, Shares underlying stock options	618,900	54,000
Granted, Shares underlying stock options	577,600	567,876
Restricted stock awards, Shares underlying stock options		-2,976
Exercised, Shares underlying stock options	-7,500	0
Forfeited, Shares underlying stock options	-7,500
Outstanding ending balance, Shares underlying stock options	1,181,500	618,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding beginning balance, Weighted - average exercise price	$9.54	$6
Granted, Weighted - average exercise price	$19.50	$9.88
Restricted stock awards, Weighted - average exercise price		$0
Exercised, Weighted - average exercise price	$7.63
Forfeited, Weighted - average exercise price	$7.63
Outstanding ending balance, Weighted - average exercise price	$14.43	$9.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding ending balance, Weighted - average remaining contractual term (yrs)	9 years 5 months 30 days
Outstanding ending balance, Aggregate intrinsic value	$5,318,774
Exercisable ending balance, Shares underlying stock options	44,127
Exercisable ending balance, Weighted - average exercise price	$10.19
Exercisable ending balance, Weighted - average remaining contractual term (yrs)	9 years 1 month 10 days
Exercisable ending balance, Aggregate intrinsic value	358,024
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Vested and expected to vest ending balance, Shares underlying stock options	1,181,500
Vested and expected to vest ending balance, Weighted - average exercise price	$14.43
Vested and expected to vest ending balance, Weighted - average remaining contractual term (yrs)	9 years 5 months 30 days
Vested and expected to vest ending balance, Aggregate intrinsic value	$5,318,774

Shareholders_Equity_Stock_Opti

Shareholders’ Equity (Stock Options, Valuation Assumptions) (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Equity [Abstract]
Volatility	174.00%	132.00%
Expected life (years)	6 years 9 months 25 days	6 years 1 month 10 days
Risk-free interest rate	1.80%	1.90%
Dividend yield	0.00%	0.00%

Shareholders_Equity_Summary_of

Shareholders’ Equity (Summary of Restricted Stock Awards) (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, in shares		-2,976
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance, in shares	1,279,007	1,746,853
Granted, in shares		2,976
Vested, in shares	-153,026	-423,693
Forfeited, in shares		-47,129
Ending balance in shares	1,125,981	1,279,007
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance, in usd per share	$12.86	$12.86	$11.80
Granted, in usd per share		$8.40
Vested, in usd per share	$12.87	$9.18
Forfeited, in usd per share		$4.41
Ending balance, in usd per share	$12.86	$12.86	$11.80

Commitments_and_Contingencies_

Commitments and Contingencies (Narrative) (Details) (USD $)	3 Months Ended	0 Months Ended
	Mar. 31, 2015	Jan. 30, 2015	Feb. 24, 2015
	sqft
Property Subject to or Available for Operating Lease [Line Items]
Office Space	3,713
Approximate total lease payments	$300,000
Twenty-five Month Sublease Agreement, Expiring March 31, 2017 [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease agreement period		25 months
Area of space, in sqft		4,047
Total lease payments through the end of the lease		93,000
Number of options to extend lease		2
Lease extension period		6 months
Thirty-two Month Sublease Agreement, Expiring October 31, 2017 [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease agreement period			32 months
Area of space, in sqft			18,599
Total lease payments through the end of the lease			$1,466,000